SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharmaceuticals reports many fold jump in Q4 consolidated net profit

17 May 2022 Evaluate

Glaxosmithkline Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2022.

The company has reported many fold jump in its net profit at Rs 1217.84 crore for the quarter under review as compared to Rs 12.75 crore for the same quarter in the previous year. Total income of the company increased by 5.64% at Rs 810.86 crore for Q4FY22 as compared Rs 767.56 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported many fold jump in its net profit at Rs 1219.05 crore for the quarter under review as compared to Rs 14.33 crore for the same quarter in the previous year. Total income of the company increased by 7.02% at Rs 828.39 crore for Q4FY22 as compared Rs 774.03 crore for the corresponding quarter previous year.

For the year ended March 31, 2022, the company has reported above 4-fold jump in its net profit at Rs 1690.53 crore as compared to Rs 357.57 crore for the previous year. Total income of the company increased by 8.68% at Rs 3293.73 crore for year under review as compared to Rs 3030.66 crore for year ended March 31, 2021.

For the year ended March 31, 2022, on the consolidated basis, the company has reported above 4-fold jump at Rs 1694.72 crore as compared to Rs 358.15 crore for the previous year. Total income of the company increased by 10.46% at Rs 3353.81 crore for year under review as compared to Rs 3036.18 crore for year ended March 31, 2021.

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×